Biocompatibility, endocytosis, and intracellular trafficking of mesoporous silica and polystyrene nanoparticles in ovarian cancer cells: Effects of size and surface charge groups

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 4147-4158

  Ekkapongpisit, Maneerat ^a   Giovia, Antonino ^a   Follo, Carlo ^a   Caputo, Giuseppe ^b,c   Isidoro, Ciro ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Cyanine Technology SpA   (Italy)

Author keywords

Caveolin; Imaging; Lysosomes; Nanoparticles; Ovarian cancer; Vesicular traffic

Indexed keywords

CAVEOLIN 1; CHOLESTEROL; MESOPOROUS SILICA NANOPARTICLE; NANOPARTICLE; POLYSTYRENE NANOPARTICLE; UNCLASSIFIED DRUG;

ANALYTICAL PARAMETERS; ARTICLE; BIOACCUMULATION; BIOCOMPATIBILITY UPTAKE; CANCER CELL CULTURE; CAVEOLA; CELL DEATH; CELL LABELING; CELL MEMBRANE; CELL MIGRATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CELLULAR PARAMETERS; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; ENDOCYTOSIS; FEMALE; HUMAN; HUMAN CELL; INTERNALIZATION; LYSOSOME; OVARY CANCER; PARTICLE SIZE; PHYSICAL CHEMISTRY; PILOT STUDY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURFACE CHARGE; UPTAKE EFFICIENCY;

BIOCOMPATIBLE MATERIALS; CAVEOLIN 1; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCYTOSIS; FEMALE; HUMANS; LYSOSOMES; NANOPARTICLES; OVARIAN NEOPLASMS; PARTICLE SIZE; POLYSTYRENES; SILICON DIOXIDE; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PROPERTIES;

EID: 84870338385     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S33803     Document Type: Article

References (53)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med. 2009;361:170-177.
3. Liu JR, Opipari AW, Tan L, etal. Dysfunctional apoptosome activation in ovarian cancer: implications for chemoresistance. Cancer Res. 2002;62: 924-931.
4. Mezzanzanica D, Canevari S, Cecco LD, Bagnoli M. miRNA control of apoptotic programs: focus on ovarian cancer. Expert Rev Mol Diagn. 2011;11:277-286.
5. Castino R, Démoz M, Isidoro C. Destination 'lysosome': a target organelle for tumour cell killing? J Mol Recognit. 2003;16:337-348.
6. Duvvuri M, Krise JP. Intracellular drug sequestration events associated with the emergence of multidrug resistance: a mechanistic review. Front Biosci. 2005;10:1499-1509.
7. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 2000;11:265-283.
8. Chen T, Shukoor MI, Wang R, etal. Smart multifunctional nanostructure for targeted cancer chemotherapy and magnetic resonance imaging. ACS Nano. 2011;5:7866-78673.
9. Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Theranostic nanomedicine. Acc Chem Res. 2011;44:1029-1038.
10. Caldorera-Moore ME, Liechty WB, Peppas NA. Responsive theranostic systems: integration of diagnostic imaging agents and responsive controlled release drug delivery carriers. Acc Chem Res. 2011;44:1061-1070.
11. Kievit FM, Zhang M. Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater. 2011;23:H217-H247.
12. Shapira A, Livney YD, Broxterman HJ, Assaraf YG. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat. 2011;14:150-163.
13. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006;11:812-818.
14. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res. 2010;62:90-99.
15. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Biol. 2010;188:759-768.
16. Lei T, Srinivasan S, Tang Y, etal. Comparing cellular uptake and cytotoxicity of targeted drug carriers in cancer cell lines with different drug resistance mechanisms. Nanomedicine. 2011;7:324-332.
17. Ferris DP, Lu J, Gothard C, etal. Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. Small. 2011;7:1816-1826.
18. Benezra M, Penate-Medina O, Zanzonico PB, etal. Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest. 2011;121:2768-2780.
19. Rosenholm JM, Meinander A, Peuhu E, etal. Targeting of porous hybrid silica nanoparticles to cancer cells. ACS Nano. 2009;3:197-206.
20. Lee S, Yun HS, Kim SH. The comparative effects of mesoporous silica nanoparticles and colloidal silica on inflammation and apoptosis. Biomaterials. 2011;32:9434-9443.
21. Wang T, Zhang L, Su Z, Wang C, Liao Y, Fu Q. Multifunctional hollow mesoporous silica nanocages for cancer cell detection and the combined chemotherapy and photodynamic therapy. ACS Appl Mater Interfaces. 2011;3:2479-2486.
22. 2induces apoptosis via activation of p53 and Bax mediated by oxidative stress in human hepatic cell line. Toxicol In Vitro. 2010;24:751-758.
23. Lu X, Qian J, Zhou H, etal. In vitro cytotoxicity and induction of apoptosis by silica nanoparticles in human HepG2 hepatoma cells. Int J Nanomedicine. 2011;6:1889-1901.
24. Corbalan JJ, Medina C, Jacoby A, Malinski T, Radomski MW. Amorphous silica nanoparticles trigger nitric oxide/peroxynitrite imbalance in human endothelial cells: inflammatory and cytotoxic effects. Int J Nanomedicine. 2011;6:2821-2835.
25. Giri S, Trewyn BG, Lin VS. Mesoporous silica nanomaterial-based biotechnological and biomedical delivery systems. Nanomedicine (Lond). 2007;2:99-111.
26. Lai SK, Hida K, Man ST, etal. Privileged delivery of polymer nanoparticles to the perinuclear region of live cells via a non-clathrin, non-degradative pathway. Biomaterials. 2007;28:2876-2884.
27. Lunov O, Syrovets T, Loos C, etal. Differential uptake of functionalized polystyrene nanoparticles by human macrophages and a monocytic cell line. ACS Nano. 2011;5:1657-1669.
28. Yanagisawa R, Takano H, Inoue KI, Koike E, Sadakane K, Ichinose T. Size effects of polystyrene nanoparticles on atopic dermatitis-like skin lesions in NC/NGA mice. Int J Immunopathol Pharmacol. 2010;23:131-141.
29. Smith P, Giroud M, Wiggins E, etal. Cellular entry of nanoparticles via serum sensitive clathrin-mediated endocytosis, and plasma membrane permeabilization. Int J Nanomedicine. 2012;7:2045-2055.
30. Gianotti E, Bertolino CA, Benzi C, etal. Photoactive hybrid nanomaterials: indocyanine immobilized in mesoporous MCM-41 for "in-cell" bioimaging. ACS Appl Mater Interfaces. 2009;1:678-687.
31. Castino R, Peracchio C, Salini A, etal. Chemotherapy drug response in ovarian cancer cells strictly depends on a cathepsin D-Bax activation loop. J Cell Mol Med. 2009;13:1096-1109.
32. Straubinger RM, Lopez NG, Debs RJ, Hong K, Papahadjopoulos D. Liposome-based therapy of human ovarian cancer: parameters determining potency of negatively charged and antibody-targeted liposomes. Cancer Res. 1988;48:5237-5245.
33. Hamelers IH, Staffhorst RW, Voortman J, etal. High cytotoxicity of cisplatin nanocapsules in ovarian carcinoma cells depends on uptake by caveolae-mediated endocytosis. Clin Cancer Res. 2009;15:1259-1268.
34. Wiechen K, Diatchenko L, Agoulnik A, etal. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol. 2001;159:1635-1643.
35. Burghardt RC, Barhoumi R, Lewis EH, etal. Patulin-induced cellular toxicity: a vital fluorescence study. Toxicol Appl Pharmacol. 1992;112: 235-244.
36. Castino R, Fiorentino I, Cagnin M, Giovia A, Isidoro C. Chelation of lisosomal iron protects dopaminergic SH-SY5Y neuroblastoma cells from hydrogen peroxide toxicity by precluding autophagy and Akt dephosphorylation. Toxicol Sci. 2011;123:523-541.
37. Ekkapongpisit M, Giovia A, Nicotra G, Ozzano M, Caputo G, Isidoro C. Labeling and exocytosis of secretory compartments in RBL mastocytes by polystyrene and mesoporous silica nanoparticles. Int J Nanomedicine. 2012;7:1829-1840.
38. Lakadamyali M, Rust MJ, Zhuang X. Ligands for clathrin-mediated endocytosis are differentially sorted into distinct populations of early endosomes. Cell. 2006;124:997-1009.
39. Pichler H, Riezman H. Where sterols are required for endocytosis. Biochim Biophys Acta. 2004;1666:51-61.
40. Kilsdonk EP, Yancey PG, Stoudt GW, etal. Cellular cholesterol efflux mediated by cyclodextrins. J Biol Chem. 1995;270:17250-17256.
41. Dombu CY, Kroubi M, Zibouche R, Matran R, Betbeder D. Characterization of endocytosis and exocytosis of cationic nanoparticles in airway epithelium cells. Nanotechnology. 2010;21:355102.
42. Park MV, Neigh AM, Vermeulen JP, etal. The effect of particle size on the cytotoxicity, inflammation, developmental toxicity and genotoxicity of silver nanoparticles. Biomaterials. 2011;32:9810-9817.
43. Lu J, Liong M, Zink JI, Tamanoi F. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small. 2007;3: 1341-1346.
44. Xia T, Kovochich M, Liong M, Zink JI, Nel AE. Cationic polystyrene nanosphere toxicity depends on cell-specific endocytic and mitochondrial injury pathways. ACS Nano. 2008;2:85-96.
45. Gessner A, Lieske A, Paulke BR, Müller RH. Functional groups on polystyrene model nanoparticles: influence on protein adsorption. J Biomed Mater Res A. 2003;65:319-326.
46. Nel AE, Mädler L, Velegol D, etal. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater. 2009;8:543-557.
47. Dausend J, Musyanovych A, Dass M, etal. Uptake mechanism of oppositely charged fluorescent nanoparticles in HeLa cells. Macromol Biosci. 2008;8:1135-1143.
48. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin-and caveolae-mediated endocytosis. Biochem J. 2004;377:159-169.
49. Johnston HJ, Semmler-Behnke M, Brown DM, Kreyling W, Tran L, Stone V. Evaluating the uptake and intracellular fate of polystyrene nanoparticles by primary and hepatocyte cell lines in vitro. Toxicol Appl Pharmacol. 2010;242:66-78.
50. dos Santos T, Varela J, Lynch I, Salvati A, Dawson KA. Effects of transport inhibitors on the cellular uptake of carboxylated polystyrene nanoparticles in different cell lines. PLoS One. 2011;6:e24438.
51. Merhi M, Dombu CY, Brient A, etal. Study of serum interaction with a cationic nanoparticle: Implications for in vitro endocytosis, cytotoxicity and genotoxicity. Int J Pharm. 2012;423:37-44.
52. Baier G, Costa C, Zeller A, etal. BSA adsorption on differently charged polystyrene nanoparticles using isothermal titration calorimetry and the influence on cellular uptake. Macromol Biosci. 2011;11:628-638.
53. Fazlollahi F, Angelow S, Yacobi NR, etal. Polystyrene nanoparticle trafficking across MDCK-II. Nanomedicine. 2011;7:588-594.